Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may demonstrate superior weight loss outcomes compared to semaglutide, which only targets GLP-1. Notably, the Phase 2 VENTURE ...
ST. PETERSBURG, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Superior Group of Companies, Inc. (NASDAQ: SGC) today announced that Michael Benstock, Chairman, President and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
